Germany's Drager back in the black:
This article was originally published in Clinica
German company Drager Medical, which manufactures monitoring devices and ventilation equipment, saw sales rise 10% to E805 million ($699 million) during 2001 compared with the previous year. Lubeck-based Drager Medical undertook an extensive restructuring programme in 2000, aimed at cutting costs over a three-year period (see Clinica No 930, p 12). The initial cost of this programme hit profits both for Drager Medical and parent company Drager Group in 2000. They are now back in the black in terms of EBIT. Drager Group expects a sales increase in excess of 5% for 2002, based mainly on the strong market positions of Drager Medical and Drager Safety, the parent company says.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.